Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

Share on linkedin
Share on facebook
Share on twitter
Share on email

Astellas Pharma Inc. (TSE: 4503, President and
CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE: PFE) has announced the
amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized,
double-blind, placebo-controlled study evaluating the efficacy and safety of XTANDI
(enzalutamide) in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer
(CRPC). The primary endpoint remains the same: metastasis-free survival (MFS). The main
purpose of the amendment is to revise the plan for the analyses of the primary and several
secondary endpoints, which allows for a reduction in the target sample size to approximately
1,440, from 1,560 patients. The companies now anticipate PROSPER top-line results will be
disclosed later this year. Previously the expected primary completion date for PROSPER was
June 2019.
“XTANDI is already a standard of care for men worldwide fighting metastatic castrationresistant
prostate cancer, but we are continually looking to evaluate this medicine for men
facing earlier stage disease,” said Steven Benner, M.D., senior vice president and global
therapeutic area head, oncology development, Astellas. “By amending the protocol for
PROSPER, we hope to be able to accelerate the evaluation of the data in this area of medical
need.”
“PROSPER is one of a number of large, randomized trials in our robust, registration-focused
development program, where we are evaluating enzalutamide in different prostate cancer
populations, including men with earlier stages of the disease,” said Mace Rothenberg, MD,
chief development officer, Oncology, Pfizer Global Product Development. “We look forward to
2
building upon the extensive body of clinical evidence that has been generated over the past
five years and established XTANDI as a standard of care for men with metastatic CRPC.”
XTANDI is approved by the U.S. Food and Drug Administration for the treatment of patients
with metastatic CRPC, based on clinical studies showing statistically significant overall
survival benefit versus placebo.
Details regarding the protocol amendment for PROSPER (NCT02003924) will be available on
ClinicalTrials.gov.

Share on linkedin
Share on facebook
Share on twitter
Share on email

Subscribe

The Canadian Business Quarterly (The CBQ) provides an in-depth view of business and economic development issues taking place across the country. Featuring interviews with top executives, government policy makers and prominent industry bodies The CBQ examines the news beyond the headlines to uncover the drivers of local, provincial, and national affairs.

All copy appearing in The Canadian Business Quarterly is copyrighted. Reproduction in whole or part is not permitted without written permission. Any financial advice published in The Canadian Business Quarterly or on www.thecbq.ca has been prepared without taking in to account the objectives, financial situation or needs of any reader. Neither The Canadian Business Quarterly nor the publisher nor any of its employees hold any responsibility for any losses and or injury incurred (if any) by acting on information provided in this magazine or website. All opinions expressed are held solely by the contributors and are not endorsed by The Canadian Business Quarterly or www.thecbq.ca.

All reasonable care is taken to ensure truth and accuracy, but neither the editor nor the publisher can be held responsible for errors or omissions in articles, advertising, photographs or illustrations. Unsolicited manuscripts are welcome but cannot be returned without a stamped, self-addressed envelope. The publisher is not responsible for material submitted for consideration. The CBQ is published by Romulus Rising Pty Ltd, ABN: 77 601 723 111.

Subscribe

© 2020 The Canadian Business Quarterly. All rights reserved. A division of Romulus Rising Pty Ltd, an Australian media company (www.RomulusRising.com).